This article provides an overview of the field of biological and biosimilar medicines in the treatment of allergy and immunologic disorders. Researchers began by discussing the evolution of asthma therapy, progressing to daily biological treatments, and finishing with an economic perspective. Omalizumab is now the only pharmacological–biological therapy authorized for allergic disorders. Several additional monoclonal antibodies are presently undergoing premarketing trials, however, the prices of these treatments are challenging for healthcare systems to maintain.
Several biological therapies have either expired or are about to expire, allowing biosimilars to enter the drug market. In this approach, it will be feasible in the future to cut healthcare expenditures while also increasing access to medicines that are presently out of reach for all patients.
Reference: https://journals.lww.com/co-allergy/Abstract/2016/02000/Biosimilars_in_allergic_diseases.12.aspx
